Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US.

Shareholders of Dova Pharmaceuticals will be paid upfront $27.50 per share in cash plus one non-tradeable Contingent Value Right (CVR) that will give them an additional $1.50 per share in cash subject to regulatory approval of the company’s drug candidate DOPTELET for the treatment of chemotherapy-induced thrombocytopenia (CIT).

Guido Oelkers – President and CEO of Sobi, commenting on Sobi acquisition of Dova Pharmaceuticals, said: “The cadence of upcoming launches and approvals across indications and regions that Doptelet provides, enables us to further accelerate growth in our haematology franchise.

“There is a large unmet medical need within thrombocytopenia and for us this is a great opportunity to be able to give patients access to new and improved treatments. Furthermore, we are excited to welcome the 125 professionals from Dova who will greatly strengthen Sobi’s haematology infrastructure and broaden our value chain in the US.”

Sobi acquisition of Dova Pharmaceuticals. Photo courtesy of I99pema/Wikipedia.org.

Sobi said that it will look to make use of its strong global presence to maximize the availability and commercial potential of DOPTELET across the world.

Sobi acquisition of Dova Pharmaceuticals has been approved unanimously by the boards of directors of the two companies and is anticipated to be wrapped up in Q4 2019.

Commenting on Sobi acquisition of Dova Pharmaceuticals, David Zaccardelli – President and CEO of Dova Pharmaceuticals said: “We are extremely pleased to announce this merger with Sobi, which we believe will continue the expansion of DOPTELET in the U.S., and provide the necessary resources to maximize DOPTELET’s availability to patients in both the US and internationally.

“On behalf of the Board of Directors, I’d like to thank our employees and shareholders for their continued support and dedication to our mission of providing novel and effective therapeutic options for patients with thrombocytopenia; we believe Sobi is ideally positioned to continue that mission.”

For more pharma acquisition news like Sobi acquisition of Dova Pharmaceuticals, keep following Pharma News Daily.

Related posts

• Vascular Perfusion to advance organ transportation through ULiSSES device (0)
• Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment (0)
• Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals (0)
• Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials (0)
• Progenity buys assets of ingestible device company Medimetrics (0)
• Constellation doses first patient in phase 1 trial of CPI-0209 for cancer (0)
• Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors (0)
• Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome (0)
• Opentrons launches fully automated thermocycler at $4,000 (0)
• Avior Bio to advance kidney disease treatment through Sono-Tek ultrasonic coating equipment (0)

The post Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal appeared first on PharmaNewsDaily.com.